ExcellGene
ExcellGene SA is a privately held Swiss biotech service provider founded in 2001 and headquartered in Monthey, Switzerland. It serves the pharmaceutical and biotechnology industry with science-driven personalized medicine outsourcing and bioprocess services, operating with 51–100 employees.
- Company typePrivate
- Founded2001
- HeadquartersMonthey, Switzerland
- Headcount51–100
- GTM typeB2B
- OfferingServices
What ExcellGene does
ExcellGene SA is a privately held Swiss service provider to the pharmaceutical and biotechnology industry, founded in 2001 and headquartered in Monthey, Switzerland. The company positions itself as a science and technology-driven provider operating within the Personalized Medicine Outsourcing Market, indicating a specialization in custom bioprocess and cell-line-related services for pharma/biotech clients rather than off-the-shelf product sales.
The company operates at a focused scale of 51–100 employees, a footprint consistent with a specialized contract services firm rather than a high-volume commodity producer. Its leadership is anchored by Founder and Chief Scientific Officer Wurm Florian, signaling a technically led organization. While the available data does not enumerate a discrete product portfolio or specific platform architecture, the company's classification within personalized medicine outsourcing implies that its revenue mechanics are likely tied to project-based or contract service engagements — typically milestone- or deliverable-based fees for cell line development, process development, and related bioprocess work — rather than a transactional product revenue model.
No publicly disclosed pricing, named customers, partnership network, regulatory certifications, or product launches are recorded in the available data, which materially limits visibility into the specifics of the business model, customer concentration, and go-to-market mechanics. The company maintains an active corporate website (excellgene.com) but no public disclosures of funding history, ownership structure, or financial performance are present in the source set.
ExcellGene firmographics
Firmographics- Name
- ExcellGene
- Website
- https://excellgene.com
- Company type
- Private
- Founded year
- 2001
- Headcount range
- 51–100 employees
- Short description
- ExcellGene SA is a privately held Swiss biotech service provider founded in 2001 and headquartered in Monthey, Switzerland. It serves the pharmaceutical and biotechnology industry with science-driven personalized medicine outsourcing and bioprocess services, operating with 51–100 employees.
- Ownership category
- akta.pro rank
Where ExcellGene is headquartered
LocationHeadquarters
- HQ city
- Monthey
- HQ country
- Switzerland
- HQ region
- Europe
Markets served
ExcellGene business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure
ExcellGene product offering
Product offeringCore offering
ExcellGene SA is an established, science and technology-driven service provider to the pharmaceutical and biotechnology industry. The company operates within the Personalized Medicine Outsourcing Market, offering contract services that support personalized medicine development for pharma/biotech clients.
Product overview
ExcellGene is a company operating in the biotechnology/life sciences sector. Based on market intelligence reports, it operates within the Personalized Medicine Outsourcing Market. No detailed product portfolio information is available from the provided sources.
Differentiator
Problem solved
Functional benefit
Products and services
- Pharma/Biotech Contract Services
Companies that use ExcellGene
Customer profileIdeal customer profiles1 record
ExcellGene technology and API
TechnologyTechnology focussed No
API detail
- API docs
- API detail
Core technology
AI maturity
App detail
ExcellGene partnerships and signals
Strategic signalRecent moves2 records
Expansion highlights1 record
ExcellGene competitors and assessment
Company assessmentBroad incumbents
- Fujifilm Diosynth Biotechnologies: Global CDMO providing biologics process development, manufacturing, and fill-finish services. Comparable outsourcing partner for pharma/biotech sponsors across recombinant proteins and advanced therapies.
- WuXi Biologics: Global biologics CDMO offering end-to-end discovery, development, and manufacturing services. Comparable as a biologics outsourcing provider targeting pharma/biotech sponsors, though at much larger scale and broader scope.
- AGC Biologics: Global CDMO providing mammalian and microbial biologics development and manufacturing. Comparable service portfolio to ExcellGene for pharma/biotech sponsors, with substantially greater capacity and global footprint.
- Samsung Biologics: Korean-based global CDMO offering large-scale biologics manufacturing and development services. Comparable biologics CDMO targeting similar pharma/biotech customers, with far greater manufacturing capacity.
- Catalent: Global CDMO offering biologics development, cell line services, and manufacturing. Comparable as a biologics outsourcing partner for pharma/biotech, with broader modalities and substantially larger scale.
- Lonza: Swiss-headquartered global CDMO leader offering mammalian cell line development, biologics manufacturing, and personalized medicine services. Directly comparable as a Swiss-rooted biologics CDMO, though at vastly larger scale and broader service breadth than ExcellGene.
Others
- Boehringer Ingelheim BioXcellence: Contract manufacturing arm of Boehringer Ingelheim offering biologics process development and GMP manufacturing. Comparable as a biologics CDMO for pharma/biotech, though substantially larger and part of a global pharma parent.
Direct peers
- Rentschler Biopharma: European-headquartered CDMO specializing in biologics process development and manufacturing. Highly comparable to ExcellGene as a mid-sized European biologics services provider serving pharma/biotech clients.
- LakePharma (Curia): US-based biologics CDMO specializing in antibody/protein engineering, cell line development, and process development. Comparable to ExcellGene as a mid-sized biologics services provider targeting pharma/biotech sponsors with discovery-to-development capabilities.
- Selexis: Specialist in mammalian cell line development (CHO cells) and protein expression services for biologics developers. Highly comparable to ExcellGene's core competence in cell line engineering and recombinant protein production for pharma/biotech clients.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
ExcellGene social profiles
Digital presenceExcellGene financial estimates
Financial estimateRevenue estimate
Valuation estimate
ExcellGene leadership team
Management profileNumber of profiles
Profiles1 record
ExcellGene funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ExcellGene M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ExcellGene
What does ExcellGene do?
ExcellGene SA is an established, science and technology-driven service provider to the pharmaceutical and biotechnology industry. The company operates within the Personalized Medicine Outsourcing Market, offering contract services that support personalized medicine development for pharma/biotech clients.
When was ExcellGene founded?
ExcellGene was founded in 2001. It employs 51 to 100 people.
Where is ExcellGene based?
ExcellGene is headquartered in Monthey, Switzerland, in the Europe region.
Who are ExcellGene's main competitors?
Broad incumbents on record are Fujifilm Diosynth Biotechnologies, WuXi Biologics, AGC Biologics, Samsung Biologics, Catalent and Lonza. Boehringer Ingelheim BioXcellence is listed as an others. Direct peers are Rentschler Biopharma, LakePharma (Curia) and Selexis.